- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01968993
Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine
A Prospective, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using nanOss Bioactive and Autograft Bone.
Study Overview
Status
Intervention / Treatment
Detailed Description
The post market clinical investigation is designed to assess instrumented posterolateral fusion (PLF) using nanOss Bioactive bone void filler with autograft bone and bone marrow aspirate in patients with symptomatic spinal stenosis secondary to degenerative disc disease with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1.
Preoperatively, the participant will provide his/her medical history and complete self assessment forms. The investigator will perform a clinical evaluation and x-rays will be performed if recent x-rays are not available. Participants will undergo instrumented PLF with an interbody fusion device (with autograft or allograft) using nanOss Bioactive in combination with autograft bone and bone marrow aspirate in one posterolateral gutter and autograft alone in the opposite posterolateral gutter.
Following surgery, operative and discharge information will be collected and a clinical evaluation will be performed prior to discharge. Participants will be evaluated 6 and 12 months postoperatively. One investigational site will participate in long-term followup of 24 months. Each participant will complete x-rays and self assessment documents. A CT scan performed at the 12 month postoperative visit will be evaluated by an independent radiologist to assess fusion results. Complication data will be recorded throughout the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Green Hospital
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- Columbia Orthopedic Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- is at least 18 years of age and skeletally mature.
- must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc disease (DDD) at one or two adjacent levels from L2-S1 requiring a fusion.
- must have completed a minimum of three months of unsuccessful conservative, non-operative care.
- must have discogenic back pain with or without leg pain.
- DDD must be confirmed by MRI or CT scans followed by discography (if necessary).
- must score at least 40% on the Oswestry Disability Index.
- must score at least a 4 on a 10 cm Visual Analog Scale for back pain.
- must be able to comply with the protocol's follow-up schedule.
- must understand and sign the informed consent document.
Exclusion Criteria:
- symptomatic at more than 2 levels.
- previous fusion surgery at any lumbar level with or without instrumentation (prior discectomy, laminotomy, laminectomy or nucleolysis at the operative (involved) level > 6 months is permitted).
- more than 50% spondylolisthesis.
- lumbar scoliosis greater than 11 degrees.
- osteoporosis, osteopenia, osteomalacia, Paget's disease or metabolic bone disease.
- spinal tumors.
- active arachnoiditis.
- fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
- impaired calcium metabolism.
- active infection or surgical site infection.
- rheumatoid arthritis or other autoimmune disease
- chronic steroid use (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing.
- systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis.
- morbid obesity defined as body mass index (BMI)>40 or a weight more than 100lbs over ideal body weight.
- smokers unless the patient agrees to quit at least 2 weeks prior to and for the duration of the study, confirmed by a carboxyhemoglobin test prior to surgery.
- psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse.
- active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years.
- documented allergies to porcine collagen or titanium
- pregnancy, or interested in becoming pregnant in the next four years.
- participation in another investigational study within 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nanOss Bioactive - posterolateral gutter
Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side.
Autograft alone will be used in the opposite posterolateral gutter.
|
Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side.
Autograft alone will be used in the opposite posterolateral gutter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fusion
Time Frame: 12 months
|
Based on x-ray and CT scan.
Defined as bridging trabecular bone and less than 3mm of translational motion and less than 5mm of angular motion.
X-rays obtained at 6 months and 12 months.
CT obtained at 12 months.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Oswestry Disability Index score
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels
|
Preoperatively, 6 months, 12 months
|
Improvement in VAS pain scores
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels.
|
Preoperatively, 6 months, 12 months
|
Improvement in Short Form-36 scores (SF-36)
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels.
|
Preoperatively, 6 months, 12 months
|
Decrease in medication usage
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels.
|
Preoperatively, 6 months, 12 months
|
Work status
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels.
|
Preoperatively, 6 months, 12 months
|
Patient satisfaction
Time Frame: Preoperatively, 6 months, 12 months
|
As compared to baseline levels.
|
Preoperatively, 6 months, 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complications, adverse events and neurological status
Time Frame: 6 months, 12 months
|
Incidence of reoperations, revisions, supplemental fixations, neurological failures, unexpected adverse events or complications will be calculated.
Percentage of patients in each category will be reported and exact 95% confidence intervals will be calculated using the inverse beta distribution.
|
6 months, 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert Eastlack, MD, Scripps Green Hospital
- Principal Investigator: Thomas Highland, MD, Columbia Orthopedic Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
ReGelTec, Inc.Not yet recruitingDegenerative Disc Disease (DDD)
Clinical Trials on nanOss Bioactive - posterolateral gutter
-
Pioneer Surgical Technology, Inc.TerminatedDegenerative Disc Disease | Spinal Stenosis | SpondylolisthesisUnited States
-
Pioneer Surgical Technology, Inc.CompletedDegenerative Disc Disease | Spinal Stenosis | SpondylolisthesisUnited States